Details for Patent: 9,902,714

Which drugs does patent 9,902,714 protect, and when does it expire?

Patent 9,902,714 protects BALVERSA and is included in one NDA.

This patent has thirty-nine patent family members in thirty-five countries.

Summary for Patent: 9,902,714

Title:	Quinoxaline derivatives useful as FGFR kinase modulators
Abstract:	The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. ##STR00001##
Inventor(s):	Vermeulen; Wim (Vosselaar, BE), Hostyn; Steven Anna (Hove, BE), Cuyckens; Filip Albert Celine (Aartselaar, BE), Jones; Russell Mark (Binningen, CH), Broggini; Diego Fernando Domenico (Zurich, CH)
Assignee:	ASTEX THERAPEUTICS LTD (Cambridge, GB)
Application Number:	15/128,345
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Drugs Protected by US Patent 9,902,714

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No			Y
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-002	Apr 12, 2019		RX	Yes	No			Y
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-003	Apr 12, 2019		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 9,902,714

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	14161820	Mar 26, 2014

PCT Information
PCT Filed	March 26, 2015	PCT Application Number:	PCT/EP2015/056507
PCT Publication Date:	October 01, 2015	PCT Publication Number:	WO2015/144803

International Family Members for US Patent 9,902,714

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	099854
Australia	2015238300
Brazil	112016022060
Canada	2943683